OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physicianâs offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.
äŒæ¥ã³ãŒãOSUR
äŒç€ŸåOraSure Technologies Inc
äžå Žæ¥Nov 17, 1986
æé«çµå¶è²¬ä»»è
ãCEOãEglinton Manner (Carrie)
åŸæ¥å¡æ°501
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Nov 17
æ¬ç€Ÿæåšå°220 E First St
éœåžBETHLEHEM
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·18015
é»è©±çªå·15036416115
ãŠã§ããµã€ãhttps://www.orasure.com/
äŒæ¥ã³ãŒãOSUR
äžå Žæ¥Nov 17, 1986
æé«çµå¶è²¬ä»»è
ãCEOãEglinton Manner (Carrie)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã